A substrate-trapping strategy to find E3 ubiquitin ligase substrates identifies Parkin and TRIM28 targets.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
20 10 2020
Historique:
received: 08 03 2020
accepted: 28 09 2020
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 22 6 2021
Statut: epublish

Résumé

The identification of true substrates of an E3 ligase is biologically important but biochemically difficult. In recent years, several techniques for identifying substrates have been developed, but these approaches cannot exclude indirect ubiquitination or have other limitations. Here we develop an E3 ligase substrate-trapping strategy by fusing a tandem ubiquitin-binding entity (TUBE) with an anti-ubiquitin remnant antibody to effectively identify ubiquitinated substrates. We apply this method to one of the RBR-type ligases, Parkin, and to one of the RING-type ligases, TRIM28, and identify previously unknown substrates for TRIM28 including cyclin A2 and TFIIB. Furthermore, we find that TRIM28 promotes cyclin A2 ubiquitination and degradation at the G1/S phase and suppresses premature entry into S phase. Taken together, the results indicate that this method is a powerful tool for comprehensively identifying substrates of E3 ligases.

Identifiants

pubmed: 33082525
doi: 10.1038/s42003-020-01328-y
pii: 10.1038/s42003-020-01328-y
pmc: PMC7576197
doi:

Substances chimiques

Tripartite Motif-Containing Protein 28 EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
parkin protein EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

592

Références

J Biol Chem. 2013 Jul 26;288(30):22019-32
pubmed: 23754282
Nat Protoc. 2016 Feb;11(2):291-301
pubmed: 26766115
Nat Biotechnol. 2010 Aug;28(8):868-73
pubmed: 20639865
J Cell Sci. 2009 Nov 15;122(Pt 22):4208-17
pubmed: 19861496
Mol Cell. 2010 Sep 24;39(6):963-74
pubmed: 20864041
Mol Cell Biol. 1995 Aug;15(8):4347-52
pubmed: 7623829
PLoS One. 2012;7(4):e34748
pubmed: 22496854
J Cell Biol. 2008 Dec 1;183(5):795-803
pubmed: 19029340
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4630-5
pubmed: 25827227
Mol Cell. 2014 Jan 9;53(1):148-61
pubmed: 24389104
Annu Rev Biochem. 1992;61:761-807
pubmed: 1323239
Biochem J. 2016 Nov 15;473(22):4083-4101
pubmed: 27834739
Cancer Cell. 2008 Jul 8;14(1):10-21
pubmed: 18598940
J Cell Biol. 2010 Apr 19;189(2):211-21
pubmed: 20404107
Oncogene. 1995 Apr 20;10(8):1501-9
pubmed: 7731704
J Biol Chem. 2011 Jun 3;286(22):19630-40
pubmed: 21454557
Nature. 2009 Dec 3;462(7273):615-9
pubmed: 19956254
Nat Cell Biol. 2008 Jul;10(7):802-11
pubmed: 18552834
Mol Cell. 2018 Apr 19;70(2):211-227.e8
pubmed: 29656925
Cancer Res. 2015 Jan 15;75(2):344-55
pubmed: 25421577
Nat Rev Mol Cell Biol. 2009 May;10(5):319-31
pubmed: 19352404
Cell Cycle. 2009 Nov 15;8(22):3668-74
pubmed: 19844164
J Biol Chem. 2004 Apr 30;279(18):18935-43
pubmed: 14966115
Trends Biochem Sci. 2017 Apr;42(4):297-311
pubmed: 28118948
Nat Rev Mol Cell Biol. 2009 Nov;10(11):755-64
pubmed: 19851334
Annu Rev Biochem. 2009;78:399-434
pubmed: 19489725
J Cell Sci. 2008 Jul 15;121(Pt 14):2319-26
pubmed: 18559889
Nat Struct Mol Biol. 2014 Oct;21(10):876-83
pubmed: 25173174
J Cell Sci. 2012 Feb 1;125(Pt 3):531-7
pubmed: 22389392
Nature. 2013 Apr 18;496(7445):372-6
pubmed: 23503661
PLoS One. 2011;6(8):e23747
pubmed: 21876767
Nature. 1998 Apr 9;392(6676):605-8
pubmed: 9560156
EMBO Rep. 2009 Nov;10(11):1250-8
pubmed: 19798103
EMBO J. 2011 Jun 21;30(14):2853-67
pubmed: 21694720
Nature. 2010 Jan 14;463(7278):237-40
pubmed: 20075919
J Cell Biol. 2013 Jan 21;200(2):163-72
pubmed: 23319602
PLoS Genet. 2010 Mar 05;6(3):e1000869
pubmed: 20221260
Cancer Res. 2006 Dec 15;66(24):11594-9
pubmed: 17178852
J Cell Biol. 2010 Dec 27;191(7):1367-80
pubmed: 21173115
Nat Rev Cancer. 2011 Oct 07;11(11):792-804
pubmed: 21979307

Auteurs

Masashi Watanabe (M)

Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan. mawata@med.hokudai.ac.jp.

Yasushi Saeki (Y)

Laboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Tokyo, 156-8506, Japan.

Hidehisa Takahashi (H)

Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.

Fumiaki Ohtake (F)

Life Science Tokyo Advanced Research Center, Hoshi University, 2-4-41 Ebara, Shinagawa-Ku, Tokyo, 142-8501, Japan.

Yukiko Yoshida (Y)

Ubiquitin Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-Ku, Tokyo, 156-8506, Japan.

Yusuke Kasuga (Y)

Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.

Takeshi Kondo (T)

Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.

Hiroaki Yaguchi (H)

Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.

Masanobu Suzuki (M)

Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.

Hiroki Ishida (H)

Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.

Keiji Tanaka (K)

Laboratory of Protein Metabolism, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Tokyo, 156-8506, Japan.

Shigetsugu Hatakeyama (S)

Department of Biochemistry, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan. hatas@med.hokudai.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH